Multiple myeloma: therapeutic delivery of antibodies and aptamers



Pujol-Navarro N, Al Qaraghuli MM, Kubiak-Ossowska K, Alsaadi MM, Horne GA, Soutar RL, Paspali E, Ferro VA, Williams MT, Mulheran PA.


Ther Deliv. 2021 Sep 27. doi: 10.4155/tde-2021-0041. Online ahead of print.


Multiple myeloma is the second most common hematological malignancy in adults, accounting for 2% of all cancer-related deaths in the UK. Current chemotherapy-based regimes are insufficient, as most patients relapse and develop therapy resistance. This review focuses on current novel antibody- and aptamer-based therapies aiming to overcome current therapy limitations, as well as their respective limitations and areas of improvement. The use of computer modeling methods, as a tool to study and improve ligand-receptor alignments for the use of novel therapy development will also be discussed, as it has become a rapid, reliable and comparatively inexpensive method of investigation.

Keywords: .

Link/DOI: 10.4155/tde-2021-0041